Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Pancreatic Neuroendocrine Tumor (pNET) · Extra-Pancreatic Neuroendocrine Tumor (epNET)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Exelixis Clinical Site #43, Birmingham, Alabama, United States

  • Exelixis Clinical Site #36, Phoenix, Arizona, United States

  • Exelixis Clinical Site #42, Tucson, Arizona, United States

  • Exelixis Clinical Site #18, Beverly Hills, California, United States

  • Exelixis Clinical Site #16, Los Angeles, California, United States

  • Exelixis Clinical Site #54, Palo Alto, California, United States

  • Exelixis Clinical Site #12, Santa Monica, California, United States

  • Exelixis Clinical Site #29, Vallejo, California, United States

  • Exelixis Clinical Site #19, Washington D.C., District of Columbia, United States

  • Exelixis Clinical Site #35, Jacksonville, Florida, United States

  • Exelixis Clinical Site #11, Tampa, Florida, United States

  • Exelixis Clinical Site #9, Lexington, Kentucky, United States

  • Exelixis Clinical Site #23, Metairie, Louisiana, United States

  • Exelixis Clinical Site #8, Boston, Massachusetts, United States

  • Exelixis Clinical Site #47, Detroit, Michigan, United States

  • Exelixis Clinical Site #1, Grand Rapids, Michigan, United States

  • Exelixis Clinical Site #38, Rochester, Minnesota, United States

  • Exelixis Clinical Site #5, St Louis, Missouri, United States

  • Exelixis Clinical Site #25, Omaha, Nebraska, United States

  • Exelixis Clinical Site #14, Albuquerque, New Mexico, United States

  • Exelixis Clinical Site #59, Buffalo, New York, United States

  • Exelixis Clinical Site #7, New York, New York, United States

  • Exelixis Clinical Site #53, Rochester, New York, United States

  • Exelixis Clinical Site #17, Chapel Hill, North Carolina, United States

  • Exelixis Clinical Site #6, Durham, North Carolina, United States

  • Exelixis Clinical Site #57, Fargo, North Dakota, United States

  • Exelixis Clinical Site #39, Cleveland, Ohio, United States

  • Exelixis Clinical Site #28, Columbus, Ohio, United States

  • Exelixis Clinical Site #27, Portland, Oregon, United States

  • Exelixis Clinical Site #20, Philadelphia, Pennsylvania, United States

  • Exelixis Clinical Site #21, Pittsburgh, Pennsylvania, United States

  • Exelixis Clinical Site #24, Knoxville, Tennessee, United States

  • Exelixis Clinical Site #65, Nashville, Tennessee, United States

  • Exelixis Clinical Site #10, Dallas, Texas, United States

  • Exelixis Clinical Site #15, Salt Lake City, Utah, United States

  • Exelixis Clinical Site #3, Charlottesville, Virginia, United States

  • Exelixis Clinical Site #13, Fairfax, Virginia, United States

  • Exelixis Clinical Site #34, Seattle, Washington, United States

  • Exelixis Clinical Site #31, Milwaukee, Wisconsin, United States

  • Exelixis Clinical Site #40, Saint Leonards, New South Wales, Australia

  • Exelixis Clinical Site #67, Woodville South, South Australia, Australia

  • Exelixis Clinical Site #51, Clayton, Victoria, Australia

  • Exelixis Clinical Site #68, Clayton, Victoria, Australia

  • Exelixis Clinical Site #55, Herston, Australia

  • Exelixis Clinical Site #48, Graz, Austria

  • Exelixis Clinical Site #61, Ottawa, Canada

  • Exelixis Clinical Site #49, Toronto, Canada

  • Exelixis Clinical Site #63, Hong Kong, China

  • Exelixis Clinical Site 58, Berlin, Germany

  • Exelixis Clinical Site #52, Tübingen, Germany

  • Exelixis Clinical Site #75, Würzburg, Germany

  • Exelixis Clinical Site #77, China, Hong Kong

  • Exelixis Clinical Site #78, Naples, Naples, Italy

  • Exelixis Clinical Site #70, Roma, Italy

  • Exelixis Clinical Site #69, Warsaw, Masovian Voivodeship, Poland

  • Exelixis Clinical Site #45, Katowice, Poland

  • Exelixis Clinical Site #37, Warsaw, Poland

  • Exelixis Clinical Site #72, Gliwice, Ślaskie, Poland

  • Exelixis Clinical Site #2, San Juan, Puerto Rico

  • Exelixis Clinical Site # 4, San Juan, Puerto Rico

  • Exelixis Clinical Site #30, Seoul, South Korea

  • Exelixis Clinical Site #46, Seoul, South Korea

  • Exelixis Clinical Site #32, Seoul, South Korea

  • Exelixis Clinical Site #41, Seoul, South Korea

  • Exelixis Clinical Site #26, Seoul, South Korea

  • Exelixis Clinical Site #74, Santiago de Compostela, A Coruña, Spain

  • Exelixis Clinical Site #80, Oviedo, Principality of Asturias, Spain

  • Exelixis Clinical Site #76, Barcelona, Spain

  • Exelixis Clinical Site #56, Madrid, Spain

  • Exelixis Clinical Site #73, Madrid, Spain

  • Exelixis Clinical Site #44, Madrid, Spain

  • Exelixis Clinical Site #66, Murcia, Spain

  • Exelixis Clinical Site #60, Santander, Spain

  • Exelixis Clinical Site #62, Seville, Spain

  • Exelixis Clinical Site #64, Valencia, Spain

  • Exelixis Clinical Site #79, Zaragoza, Spain

  • Exelixis Clinical Site #22, London, England, United Kingdom

  • Exelixis Clinical Site #71, Oxford, England, United Kingdom

  • Exelixis Clinical Site #50, Liverpool, United Kingdom

  • Exelixis Clinical Site #33, Sheffield, United Kingdom

Study leads
  • Medical Director

    Study Director

    Exelixis